Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 5;12(3):601.
doi: 10.3390/cancers12030601.

FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma-An Updated Overview

Conrad-Amadeus Voltin  1 , Jasmin Mettler  1 , Jirka Grosse  2 , Markus Dietlein  1 , Christian Baues  3 , Christine Schmitz  4 , Peter Borchmann  5 , Carsten Kobe  1 , Dirk Hellwig  2
Affiliations
Review

FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma-An Updated Overview

Conrad-Amadeus Voltin et al. Cancers (Basel). .

Abstract

Since the mid-1990s, 18F-fluorodeoxglucose (FDG)-positron emission tomography (PET) in combination with computed tomography has come to play a prominent role in the management of malignant lymphomas. One of the first PET applications in oncology was the detection of lymphoma manifestations at staging, where it has shown high sensitivity. Nowadays, this imaging modality is also used during treatment to evaluate the individual chemosensitivity and adapt further therapy accordingly. If the end-of-treatment PET is negative, irradiation in advanced-stage Hodgkin lymphoma patients can be safely omitted after highly effective chemotherapy. Thus far, lymphoma response assessment has mainly been performed using visual criteria, such as the Deauville five-point scale, which became the international standard in 2014. However, novel measures such as metabolic tumor volume or total lesion glycolysis have recently been recognized by several working groups and may further increase the diagnostic and prognostic value of FDG-PET in the future.

Keywords: Hodgkin lymphoma; diffuse large B-cell lymphoma; positron emission tomography; response assessment; staging.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Female diffuse large B-cell lymphoma (DLBCL) patient with multifocal bone marrow involvement at baseline 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) (a), which was missed by undirected bone marrow biopsy and remitted completely after six cycles of chemoimmunotherapy (b).
Figure 2
Figure 2
Metabolic tumor volume (MTV) measurement in a patient with advanced-stage Hodgkin lymphoma based on different thresholding methods. SUV, standardized uptake value; SUVmax, maximum SUV; SUVmean, mean SUV.
See this image and copyright information in PMC

References

    1. Howlader N., Noone A.M., Krapcho M., Miller D., Brest A., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., et al. SEER Cancer Statistics Review, 1975–2016. National Cancer Institute; Bethesda, MD, USA: 2019. [(accessed on 19 November 2019)]. Available online: https://seer.cancer.gov/csr/1975_2016/
    1. Eichenauer D.A., Aleman B.M.P., André M.P.E., Federico M., Hutchings M., Illidge T., Engert A., Ladetto M. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018;29:iv19–iv29. doi: 10.1093/annonc/mdy080. - DOI - PubMed
    1. Engert A., Plütschow A., Eich H.T., Lohri A., Dörken B., Borchmann P., Berger B., Greil R., Willborn K.C., Wilhelm M., et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N. Engl. J. Med. 2010;363:640–652. doi: 10.1056/NEJMoa1000067. - DOI - PubMed
    1. André M.P.E., Girinsky T., Federico M., Reman O., Fortpied C., Gotti M., Casasnovas O., Brice P., van der Maazen R., Re A., et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial. J. Clin. Oncol. 2017;35:1786–1794. doi: 10.1200/JCO.2016.68.6394. - DOI - PubMed
    1. Gordon L.I., Hong F., Fisher R.I., Bartlett N.L., Connors J.M., Gascoyne R.D., Wagner H., Stiff P.J., Cheson B.D., Gospodarowicz M., et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496) J. Clin. Oncol. 2013;31:684–691. doi: 10.1200/JCO.2012.43.4803. - DOI - PMC - PubMed

LinkOut - more resources